试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-17
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
编号:NCT03026166登记状态:提前终止企业 / 申办者:AbbVie
药物 / 成分:Ipilimumab、Nivolumab、Rovalpituzumab tesirine
登记的停止原因(原文):Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-17
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
编号:NCT03668600登记状态:提前终止企业 / 申办者:Naurex, Inc, an affiliate of Allergan plc
药物 / 成分:Rapastinel
登记的停止原因(原文):Business decision to stop the program
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-17
Detection of miRNAs in HPA Axis Function in Healthy Subjects
编号:NCT04066647登记状态:提前终止企业 / 申办者:Cedars-Sinai Medical Center
药物 / 成分:Dexamethasone 4mg
登记的停止原因(原文):Interim analysis shows results opposite of hypothesized.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-16
The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases
编号:NCT01518959登记状态:提前终止企业 / 申办者:Semmelweis University
药物 / 成分:Cholecalciferol、oleum neutralicum
登记的停止原因(原文):Insufficient recruitment rate; technical issues with sample storage
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-16
Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding
编号:NCT02032784登记状态:提前终止企业 / 申办者:AdventHealth
药物 / 成分:octreotide、No Octreotide
登记的停止原因(原文):Difficult to enroll subjects
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-16
A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)
编号:NCT02212730登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:Pembrolizumab Pre-Resection、Surgical Resection、Pembrolizumab Post-Resection
登记的停止原因(原文):Terminated early due to low enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-16
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
编号:NCT02670083登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Crenezumab、Placebo
登记的停止原因(原文):This study was discontinued due to an interim analysis in this study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-16
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
编号:NCT02892734登记状态:提前终止企业 / 申办者:Northwestern University
药物 / 成分:Ipilimumab、Laboratory Biomarker Analysis、Nivolumab
登记的停止原因(原文):Slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-16
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
编号:NCT03114657登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Crenezumab、Placebo
登记的停止原因(原文):This study was discontinued due to an interim analysis in the BN29552 study, which indicated that Crenezumab was unlikely to meet its primary endpoint.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-16
A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy
编号:NCT03862846登记状态:提前终止企业 / 申办者:Reneo Pharma Ltd
药物 / 成分:REN001
登记的停止原因(原文):COVID-19 Pandemic sufficient data gathered to achieve the study objective
查看官方原始记录 ↗